Pembrolizumab and mesothelioma

Pembrolizumab appears to be an active drug in the treatment of mesothelioma. About 25% of patients have reduction in tumour whilst another 30% have stabilisation of disease. On average this lasts 6 months. Other immunomodulating drugs may also be effective.

The treatment however is costly.